Sandoz Patent-Cliff Exposure & CMS Drug Spending Portfolio
Sandoz (Princeton, NJ): 70 reconciled FDA prescription therapies (1.4% 2025 to 2030 cliff risk), $1.10B 2024 CMS Part D & Medicaid spend, and 20 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | Princeton, NJ |
| Reconciled FDA Portfolio Therapies | 70 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 1.4% |
| Primary Portfolio LOE Date | 2028-01-01 |
| 2024 CMS Total Public Spend | $1.10B |
| 2024 Medicare Part D Spend | $668.4M |
| 2024 Medicaid Spend | $433.8M |
| California HCAI SB 17 Filings | 20 WAC filings (max 107.0% 2-yr change) |